Biotech and ESG: Does saving lives get you extra credit? (and other musings)
Growing emphasis on ESG may be a net positive, but how do individual companies allocate resources toward tracking, reporting, or implementing additional practices when those resources might be better spent on their core business that is inherently ESG-focused?